tiprankstipranks
Arvinas and Pfizer Breast Cancer Trial Shows Promising Results
Company Announcements

Arvinas and Pfizer Breast Cancer Trial Shows Promising Results

Don't Miss our Black Friday Offers:

Arvinas Holding Company (ARVN) has issued an announcement.

Arvinas, Inc. and Pfizer have revealed promising results from their Phase 1b trial of vepdegestrant combined with palbociclib (IBRANCE®) in treating ER+/HER2- breast cancer in patients with multiple prior lines of therapy. The latest follow-up data, consistent with earlier findings, showed a high clinical benefit rate and an overall response rate, with a median progression-free survival of over 11 months, which extended to nearly 14 months at the recommended Phase 3 dose. These outcomes, presented at the 2024 ESMO Breast Cancer Annual Congress, coupled with a manageable safety profile, indicate the potential of this treatment regimen in heavily pre-treated breast cancer patients.

See more insights into ARVN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyArvinas price target lowered to $88 from $90 at BMO Capital
TheFlyArvinas initiated with an Overweight at Stephens
TheFlyArvinas price target lowered to $40 from $50 at Oppenheimer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App